QZQingyang Zhang

Qingyang Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qingyang Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    STEA: Histologically Validated and Reference-Independent Major Cell-Type Annotation for Spatial Transcriptomics Reveals Relevant Cellular Organization and Architecture of Tumor Microenvironment

    by Qian Li, Qingyang Zhang, Fanhong Zeng, Irene Oi-Lin Ng, Daniel Wai-Hung Ho

    Background: Recent advances in spatial transcriptomic technologies enable in situ gene expression profiling while preserving spatial context. This capability is particularly important for studying the tumor microenvironment (TME), where diverse and admixed cell populations interact within highly organized spatial niches that influence tumor progression and therapeutic response. However, the limited resolution of early spatial transcriptomic platforms results in each spatial spot capturing transcripts from multiple cell types, making accurate spot deconvolution or annotation a critical yet challenging step in downstream data analysis. The level of complexity will be particularly prominent in heterogeneous samples like the tumor microenvironments where multiple cell types are highly admixed and reliable single-cell reference atlases may usually be unavailable. Methods: In this paper, we developed our method called STEA, which is a novel and accurate reference-independent enrichment-based annotation algorithm for major cell type. Unlike the existing approaches, STEA does not require single-cell RNA sequencing datasets as reference, offering both flexibility and computational efficiency in execution. Results: We performed comprehensive benchmarking using a variety of simulated datasets across different platforms and scenarios and demonstrated the superior accuracy of STEA. Apart from synthetic data, we also evaluated multiple real datasets to further exemplify its practical applicability on both oncology-related and oncology-unrelated data. More importantly, we could confidently demonstrate the high concordance between prediction of STEA and histological classification by experienced pathologist. Conclusion: Our STEA algorithm provides a practical reference-independent framework to complement the cutting-edge spatial transcriptomics in genomics studies, facilitating accurate downstream high-dimensional spatial characterization of cellular and molecular landscapes, reconstruction of tissue architecture as well as cell–cell communication in malignant and non-malignant scenarios. Taken together, our comprehensive evaluation demonstrates the robustness and reliability of STEA, highlighting its potential as a valuable tool for studying complex tissue organization, particularly within heterogeneous TME.

  • Top Cited Papers
    Open Access

    Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma

    by Ao Chen, Vanilla Xin Zhang, Qingyang Zhang, Karen Man-Fong Sze, Lu Tian, Hongyang Huang, Xia Wang, Eva Lee, Jingyi Lu, Xueying Lyu, et al.

    Objective: Fat mass and obesity-associated protein (FTO), an eraser of N 6 -methyadenosine (m6A), plays oncogenic roles in various cancers. However, its role in hepatocellular carcinoma (HCC) is unclear. Furthermore, small extracellular vesicles (sEVs, or exosomes) are critical mediators of tumourigenesis and metastasis, but the relationship between FTO-mediated m6A modification and sEVs in HCC is unknown. Design: The functions and mechanisms of FTO and glycoprotein non-metastatic melanoma protein B (GPNMB) in HCC progression were investigated in vitro and in vivo. Neutralising antibody of syndecan-4 (SDC4) was used to assess the significance of sEV-GPNMB. FTO inhibitor CS2 was used to examine the effects on anti-PD-1 and sorafenib treatment. Results: FTO expression was upregulated in patient HCC tumours. Functionally, FTO promoted HCC cell proliferation, migration and invasion in vitro, and tumour growth and metastasis in vivo. FTO knockdown enhanced the activation and recruitment of tumour-infiltrating CD8 + T cells. Furthermore, we identified GPNMB to be a downstream target of FTO, which reduced the m6A abundance of GPNMB, hence, stabilising it from degradation by YTH N 6 -methyladenosine RNA binding protein F2. Of note, GPNMB was packaged into sEVs derived from HCC cells and bound to the surface receptor SDC4 of CD8 + T cells, resulting in the inhibition of CD8 + T cell activation. A potential FTO inhibitor, CS2, suppresses the oncogenic functions of HCC cells and enhances the sensitivity of anti-PD-1 and sorafenib treatment. Conclusion: Targeting the FTO/m6A/GPNMB axis could significantly suppress tumour growth and metastasis, and enhance immune activation, highlighting the potential of targeting FTO signalling with effective inhibitors for HCC therapy.